Comprehensive analysis of substernal lead removal: experience from EV ICD Pilot, Pivotal, and Continued Access Studies
Open Access
- 30 August 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (9)
Abstract
The extravascular implantable cardioverter-defibrillator (EV ICD) has been shown to be safe and effective for patients at risk of sudden cardiac death, but little is known about EV ICD lead removal in humans. This analysis aimed to characterize the EV ICD lead removal experience thus far. This was a retrospective analysis of lead removals from the EV ICD Pilot, Pivotal, and Continued Access Studies. Patients with a successful EV ICD implant who underwent lead removal were included. The main objective was lead removal success. Ancillary objectives included characterizing technique used, procedure complications, and reimplantation status. An EV ICD system was successfully implanted in 347 patients across the 3 studies (25.9% female; 53.4 ± 13.3 years; left ventricular ejection fraction: 39.7 ± 15.9). Of these patients, 29 (8.4%) underwent lead removal with a mean lead dwell time of 12.6 ± 14.3 months (0.2–58.4). The main reason for lead removal was lead dislodgement (n = 9, 31.0%). Lead removal was successful in 27/29 (93.1%) cases [100% (19/19) success rate 1 year post-implant]. Simple traction was used in 22/26 (84.6%) and extraction tools in 4/26 (15.4%) successful cases where technique was known. No complications were reported for any of the removal procedures. All 11 EV ICD reimplant attempts were successful. Complete removal of the EV ICD lead was successful in 93.1% of cases, and simple traction was sufficient in most instances. Based on these results, lead removal from the substernal space was safe and achievable up to 3 years post-implant. Characterizing the EV ICD lead removal experience from the Pilot, Pivotal, and Continued Access Studies. A high-level flowchart of patients included with a breakdown of the number of explants vs. extractions based on Heart Rhythm Society and European Heart Rhythm Association definitions. The two graphs summarize the overall results, including lead removal success and the technique used based on lead dwell time (y-axis for both graphs); each bar represents a single case and the dashed lines demarcate 1 year.Keywords
Funding Information
- Medtronic Inc
This publication has 18 references indexed in Scilit:
- First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-DefibrillatorJACC: Clinical Electrophysiology, 2020
- Subcutaneous Implantable Cardioverter-Defibrillator Lead ExtractionJACC: Clinical Electrophysiology, 2020
- Safety and In-Hospital Outcomes of Transvenous Lead Extraction for Cardiac Implantable Device–Related InfectionsJACC: Clinical Electrophysiology, 2019
- Risk Factors and Temporal Trends of Complications Associated With Transvenous Implantable Cardiac Defibrillator LeadsJournal of the American Heart Association, 2018
- 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRSEP Europace, 2018
- 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extractionHeart Rhythm, 2017
- The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction OutcomesEuropean Heart Journal, 2017
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2015
- An Entirely Subcutaneous Implantable Cardioverter–DefibrillatorNew England Journal of Medicine, 2010
- Deaths and cardiovascular injuries due to device-assisted implantable cardioverter-defibrillator and pacemaker lead extractionEP Europace, 2009